Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label, comparative, crossover study of antiplatelet effect of Crataesor versus aspirin in healthy volunteers
2005-004845-32Phase 2Active
- Sponsor
- Soria Natural, S.A.
- Start
- Feb 2006
- Countries
- 1
01
Overview
Phase 2, open-label trial of hawthorn in platelet aggregation disorder (2 arms), sponsored by Soria Natural, S.A. Primary endpoint: Primary antiplatelet aggregation effect of Crataesor. Started Feb 2006; status: active.
02
Drugs
hawthorn
03
Conditions
platelet aggregation disorder
Beyond the preview
Go deeper on 2005-004845-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004845-32.